Melanoma Anti-tumor Therapy by Nanotechnology-Based Drug Delivery Systems

Pesaru Komal and Ravi Vittal Kandisa
GITAM University, India

Melanoma is a less corporate type of skin cancer, but it is more aggressive with a high mortality rate. The World Cancer Research Fund International (GLOBOCAN 2015) estimates that there about 9,940 people are expected to die of melanoma (about 6,640 men and 3,300 women). Conventional MEL treatment includes surgery and chemotherapy, but many of the chemotherapeutic agents used present undesirable properties. Drug delivery systems are an alternative strategy by which to carry antineoplastic agents. Encapsulated drugs are advantageous due to such properties as high stability, better bioavailability, controlled drug release, a long blood circulation time, selective organ or tissue distribution, a lower total required dose, and minimal toxic side effects. This review of scientific research supports applying a nanotechnology-based drug delivery system for MEL therapy.

Biography
Komal Pesaru has completed her Bachelors of Technology from department of Biotechnology, GITAM University, Visakhapatnam, India. She currently working as a Research Scholar in the same university.